Skip Navigation
Print This Page
Share this page: More

Search Results

J1356: STEAM (Sequencing Triplet with Avastin and Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent and Sequential) Vs. Folfox/Bevacizumab in First-Line Metastatic Colorectal Cancer
Protocol Number:
Phase II
Nilofer Azad
To determine the benefits of using FOLFOXIRI/Bevacizumab vs FOLFOX/Bevacizumab as first line therapy in treatment naive patients with meatstatic colorectal cancer.
Metastatic colorectal cancer-no prior systemic treatment for metastatic Colorectal cancer, except palliative radiosesitizer; adjuvant chemotherapy completed less than 12 months prior to study consent-good physical condition with good blood counts and organ function.
Phase II This is a randomized clinical trial that is not blinded. Patients will be randomized to FOLFOX/Bevacizumab, FOLFOXIRI/Bevacizumab or sequential FOLFOXIRI/Bevacizumab(every 2 weeks for 4 months induction phase). Patient has good result and is tolerating the regimen after 4 month will continue for 2 more months. For specific study drug treatment information, please contact Rosalind Walker, RN, at
Last Update
09/17/2014 04:03 AM

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers


Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424



© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer